The rest is here:

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh